index - Epidemiology in dermatology and evaluation of therapeutics Accéder directement au contenu

DOCUMENTS

80

 

NOTICES

153

 

 

MOTS CLES

Auto-Diagnostic Primary adrenal insufficiency Apremilast Bacterial rhinosinusitis Treatment Endocrine toxicity Access to care Anti-HCV Direct Acting Antivirals DAA Infliximab Quality of life Anticancer drugs Axial spondyloarthritis Immune-related adverse events Dermatology Angiotensin receptor blockers Addiction Psoriasis Adalimumab Stability Cardiomyopathy Anxiety Psoriatic arthritis Atrial fibrillation Biologic Pharmacoepidemiology Biologic drug COVID-19 Sipuleucel-T Biomarkers Immunotherapy Biologic therapy Beta-lactam antibiotics Adolescent Azathioprine Cancer ASDAS Vigibase® Atopic dermatitis Antibiotic resistance Méta-Analyse Angiotensin-converting enzyme inhibitors Antimicrobials Autoimmunity Spondyloarthritis Abus d'antibiotiques Antibiotic misuse Auto-immune hepatitis Intensive care Graft-versus-host disease Placebo Ethics Anti-TNF Biomédicaments Glucocorticoids Aging Management Biologics Calcium channel blockers Antibiotics Cardiotoxicity Cattle Meta-Analysis Biological therapy CTLA-4 Antimicrobiens Prostate cancer Albinism Immune checkpoint inhibitors Ankylosing Cardiovascular therapy Acute Myeloid Leukaemia AML Etanercept ArtThese Burden Apre-milast Sacroiliitis Alitretinoin Epidemiology Ankylosing spondylitis Antimicrobial resistance Autoimmune diseases Care pathway Anxiété Amyloidosis Ustekinumab Alcohol Pharmacovigilance Drug reaction Arrhythmia Biological Therapy Cardiovascular risk CSK tyrosine-protein kinase Accelerometer Adverse side effects Arthritis Cardio-oncology Case-Control Studies BTK protein Drug survival Biosimilar Pharmaceuticals

 

 

 

Epidemiology in Dermatology and Evaluation of therapeutics , EA 7379

Adresse

Université Paris-Est Créteil Val de Marne (UPEC)

Campus Centre de Créteil
61 Avenue du Général de Gaulle
94010 Créteil Cedex

Courriel

emilie.sbidian@aphp.fr

Site Internet

 

Rattachement(s)

UFR de Santé

Direction

Émilie SBIDIAN

 

Axe(s) de recherche

 


[legende-image]65[/legende-image] Axe 1 : Comment mieux gérer les patients ayant développé des réactins graves aux médicaments, notamment en leur indiquant comment utiliser correctement les agents


[legende-image]65[/legende-image] Axe 2 : Rechercher les facteurs associés aux effets indesirables et à l'efficacité du médicament

 
 

COLLABORATIONS